USFDA observations at Patalganga and Kurkumbh facilities
Patalganga received six 483 observations and Kurkumbh one; official classification awaited, potentially delaying product approvals.
CIPLA / Q4-FY24 / risks
Keep the risk register visible.
Cipla · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Trade generics channel restructuring disruption
Transition to direct stockist model may cause temporary hiccups in Q1 FY25, impacting trade generics growth.
Timing uncertainty for Goa plant reinspection and Abraxane launch
Goa plant reinspection expected around July-August 2024; Abraxane launch depends on inspection outcome and subsequent 90-day process.
Potential pricing pressure in Lanreotide market
As a two-player market, pricing may vary depending on competitor actions, though management aims to grow total value.